Adjuvant encorafenib & binimetinib vs. placebo in fully resected stage IIB/C BRAF V600E/K mutated melanoma: a randomized triple-blind phase III study in collaboration with the EORTC Melanoma Group

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date9/09/22 → 29/04/26

Keywords

  • Clinical trial
  • Melanoma
  • EORTC Melanoma Group